Ticker,Title,Link
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,8/28/2024 3:00:00 PM
EDIT,Editas Medicine Hold Rating with Revised Price Target Amidst Mixed Financial Signals,8/9/2024 12:28:01 PM
EDIT,"BofA upgrades Editas to buy, cites reni-cel progress",8/8/2024 6:03:23 PM
EDIT,TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT),8/7/2024 4:15:39 PM
EDIT,Here is the next potential market catalyst,8/6/2024 10:00:53 PM
EDIT,Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update,7/31/2024 1:00:00 PM
EDIT,"Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more",7/28/2024 12:00:00 PM
EDIT,3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition,7/17/2024 3:30:00 PM
EDIT,3 Profitable CRISPR Stocks Earning Analysts’ Praise,7/9/2024 11:59:00 AM
EDIT,The 3 Best Gene Editing Stocks to Buy in July 2024,7/8/2024 1:00:00 PM
EDIT,Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich,6/27/2024 1:33:11 AM
EDIT,3 Gene Editing Stocks That Could Make Your Grandchildren Rich,6/25/2024 12:00:00 PM
EDIT,Wall Street Analysts Are Neutral on Top Healthcare Picks,6/19/2024 5:10:27 AM
EDIT,Unveiling 5 Analyst Insights On Editas Medicine,6/18/2024 7:00:49 PM
EDIT,Editas Medicine (EDIT) Receives a Buy from Wells Fargo,6/16/2024 12:05:46 PM
EDIT,"Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress",6/14/2024 9:01:00 AM
EDIT,The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts,5/30/2024 6:00:14 PM
EDIT,Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June,5/14/2024 4:00:00 PM
EDIT,Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting,5/10/2024 12:00:00 PM
EDIT,Editas Medicine upgraded at J.P. Morgan on recent weakness,5/9/2024 12:59:08 PM
EDIT,"EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024",5/8/2024 3:55:06 PM
EDIT,Editas Medicine Q1 2024 Earnings Preview,5/7/2024 3:39:30 PM
EDIT,"Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more",5/5/2024 12:00:00 PM
EDIT,"Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit",5/3/2024 7:00:00 PM
EDIT,Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events,5/2/2024 1:00:00 PM
EDIT,"Editas, Bristol Myers extend T cell therapy collaboration",5/1/2024 4:12:21 PM
EDIT,"EDIT, CLNE and NIU are among after hour movers",4/26/2024 9:00:42 PM
EDIT,Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting,4/22/2024 10:31:00 PM
EDIT,Biotech Roundtable: Who will bring the next CRISPR drug to market?,4/2/2024 3:36:00 PM
EDIT,Biotech Roundtable: Is CRISPR all it's cracked up to be?,3/26/2024 3:43:00 PM
EDIT,Editas Medicine (EDIT) Receives a New Rating from a Top Analyst,3/5/2024 12:25:56 PM
EDIT,Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism,3/1/2024 6:17:52 AM
EDIT,The Latest Analyst Ratings For Editas Medicine,2/29/2024 6:00:24 PM
EDIT,Editas Medicine files for mixed shelf offering,2/28/2024 10:43:15 PM
EDIT,Editas Medicine Q4 2023 Earnings Preview,2/27/2024 5:23:58 PM
EDIT,Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events,2/21/2024 1:00:00 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,1/31/2024 3:00:00 PM
EDIT,7 Mighty Healthcare Stocks Changing the Game of Medicine,1/17/2024 5:04:45 PM
EDIT,Optimistic Outlook for Editas Medicine Driven by Therapeutic Development and Regulatory Advancements,1/12/2024 10:51:56 AM
EDIT,3 Stocks to Buy in the Booming Field of Gene Editing,1/11/2024 9:38:39 PM
EDIT,Buy Rating for Editas Medicine Backed by Strong SCD Program and Promising Clinical Developments,1/9/2024 10:17:54 AM
EDIT,Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference,1/8/2024 2:15:00 PM
EDIT,RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT),1/6/2024 1:47:04 AM
EDIT,Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference,1/3/2024 1:00:00 PM
EDIT,Buy Rating Affirmed for Editas Medicine Amid Strategic Partnerships and Promising Treatment Data,12/13/2023 4:55:29 PM
EDIT,The Latest Analyst Ratings for Editas Medicine,12/12/2023 5:00:19 PM
EDIT,"Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar",12/11/2023 6:00:00 PM
EDIT,"If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names",11/29/2023 7:28:48 PM
EDIT,Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year,11/22/2023 11:30:00 AM
EDIT,The 3 Best Gene Editing Stocks on the Frontier of Medicine,11/20/2023 10:43:50 PM
EDIT,3 Long-Term Growth Stocks Analysts Are Bullish On,11/16/2023 8:25:54 PM
EDIT,3 Biotech Stocks That Are Betting on the Future of Gene Editing ,11/9/2023 8:37:06 PM
EDIT,Analysts Offer Insights on Healthcare Companies: IN8bio (INAB) and Editas Medicine (EDIT),11/8/2023 6:50:44 AM
EDIT,Truist Financial Keeps Their Buy Rating on Editas Medicine (EDIT),11/7/2023 2:26:26 AM
EDIT,RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT),11/6/2023 12:07:05 PM
EDIT,Positive Outlook for Editas Medicine: Progress in Clinical Trials and Proactive Off-Target Analysis Bolsters Buy Rating,11/5/2023 11:58:00 PM
EDIT,Geulah Livshits Rates Editas Medicine as ‘Buy’: Promising Clinical Trials and Stable Financial Outlook,11/3/2023 9:06:26 PM
EDIT,Editas Medicine is about to announce earnings — here's what Wall Street expects,11/2/2023 3:01:13 PM
EDIT,Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events,10/27/2023 1:00:00 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023",10/24/2023 5:00:44 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023",10/18/2023 5:00:31 PM
EDIT,Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst,10/17/2023 8:35:56 PM
EDIT,Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease,10/16/2023 2:00:00 PM
EDIT,Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session,9/29/2023 8:10:28 PM
EDIT,Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer,9/25/2023 10:30:00 PM
EDIT,Editas Medicine Announces Upcoming Investor Events,8/30/2023 3:00:00 PM
EDIT,Analyst Expectations for Editas Medicine's Future,8/29/2023 6:00:35 PM
EDIT,Bluebird bio favored at Baird as sickle cell disease space gets busy,8/24/2023 7:42:35 PM
EDIT,Truist Financial Sticks to Their Buy Rating for Editas Medicine (EDIT),8/7/2023 2:27:18 AM
EDIT,RBC Capital Sticks to Its Hold Rating for Editas Medicine (EDIT),8/5/2023 1:46:53 AM
EDIT,Bank of America Securities Sticks to Its Hold Rating for Editas Medicine (EDIT),8/4/2023 9:55:13 AM
EDIT,Expert Ratings for Editas Medicine,8/3/2023 2:00:45 PM
EDIT,"Editas Medicine GAAP EPS of -$0.56 beats by $0.21, revenue of $2.89M misses by $1.5M",8/2/2023 11:07:50 AM
EDIT,Editas Medicine Q2 2023 Earnings Preview,8/1/2023 4:56:07 PM
EDIT,"Editas, Azzur expand manufacturing partnership",7/27/2023 3:15:52 PM
EDIT,Editas Medicine appoints Burkly as Chief Scientific Officer,7/24/2023 3:31:46 PM
EDIT,SVB Securities Sticks to Its Hold Rating for Editas Medicine (EDIT),6/26/2023 6:45:29 AM
EDIT,Robert W. Baird Remains a Buy on Editas Medicine (EDIT),6/22/2023 9:55:44 AM
EDIT,You can now fix those embarrassing mistakes by editing your WhatsApp messages and iMessages – here's how,6/16/2023 11:46:05 AM
EDIT,Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,6/15/2023 7:12:48 PM
EDIT,Editas Medicine shares slip after proposing $125M stock offering,6/14/2023 8:24:29 PM
EDIT,What 6 Analyst Ratings Have To Say About Editas Medicine,6/13/2023 7:01:43 PM
EDIT,Editas upgraded to overweight at Raymond James on sickle cell candidate,6/12/2023 6:20:53 PM
EDIT,"Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders",6/9/2023 5:29:18 PM
EDIT,"Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?",6/6/2023 8:15:10 PM
EDIT,Novo Nordisk in pact with Life Edit Therapeutics for gene editing,5/24/2023 11:24:00 AM
EDIT,7 Short-Squeeze Stocks Set for a May Rally,5/22/2023 9:38:33 PM
EDIT,"Editas Medicine appoints Erick Lucera as CFO, Michelle Robertson steps down",5/16/2023 8:58:22 PM
EDIT,"ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session",5/15/2023 12:38:12 PM
EDIT,Citigroup Sticks to Their Hold Rating for Editas Medicine (EDIT),5/12/2023 10:45:48 AM
EDIT,Oppenheimer Sticks to Their Hold Rating for Editas Medicine (EDIT),5/9/2023 4:26:26 PM
EDIT,6 Analysts Have This to Say About Editas Medicine,5/8/2023 10:02:12 PM
EDIT,"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Editas Medicine (EDIT) and Tiziana Life Sciences (TLSA)",5/5/2023 3:50:07 PM
EDIT,Editas Medicine Q1 2023 Earnings Preview,5/4/2023 4:39:28 PM
EDIT,The 3 Most Promising Gene Editing Stocks to Buy in 2023,4/28/2023 8:51:00 PM
EDIT,Editas sickle cell candidate granted FDA Orphan Drug designation,4/27/2023 1:24:19 PM
EDIT,Robert W. Baird Sticks to Its Buy Rating for Editas Medicine (EDIT),4/19/2023 5:55:24 AM
EDIT,Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session,4/17/2023 7:27:38 PM
EDIT,Gene editing stocks rally as Wall Street turns bullish,4/13/2023 7:59:42 PM
EDIT,RBC Capital Remains a Hold on Editas Medicine (EDIT),4/8/2023 1:46:17 AM
EDIT,7 Biotech Stocks to Buy for Breakthrough Treatments and Cures,3/30/2023 12:54:48 AM
EDIT,The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket,3/25/2023 1:17:25 PM
EDIT,"EDIT, AVXL and ILPT are among consumer movers",3/14/2023 9:10:46 PM
EDIT,Editas Medicine (EDIT) Gets a Hold from SVB Securities,2/27/2023 5:05:43 AM
EDIT,Editas Medicine (EDIT) Receives a Hold from RBC Capital,2/23/2023 4:26:25 PM
EDIT,"Editas rises on Q4 revenue beat, gene-editing therapy data for sickle cell disease by mid-year",2/22/2023 5:28:54 PM
EDIT,Editas Medicine Q4 2022 Earnings Preview,2/21/2023 4:09:21 PM
EDIT,3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later,2/2/2023 5:58:23 PM
EDIT,"Editas, Beam win bullish views as Cantor launches gene editing coverage",2/1/2023 7:07:28 PM
EDIT,7 CRISPR Stocks With the Best Long-Term Potential ,1/31/2023 12:10:35 AM
EDIT,Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT),1/24/2023 4:26:19 PM
EDIT,SVB Securities Sticks to Its Hold Rating for Editas Medicine (EDIT),1/23/2023 12:25:22 PM
EDIT,"Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies",1/19/2023 3:37:00 PM
EDIT,3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years,1/18/2023 8:40:13 PM
EDIT,Analyst Expectations for Editas Medicine's Future,1/10/2023 7:00:38 PM
EDIT,"Editas Medicine To Reduce Headcount By 20% As Part Of Reprioritization, CSO To Stepdown ",1/9/2023 2:49:36 PM
EDIT,"Beam Therapeutics a buy at Citi on genetic editing platform, pipeline",12/13/2022 5:01:21 PM
EDIT,Editas Medicine (EDIT) Receives a Buy from Robert W. Baird,12/9/2022 5:55:43 AM
EDIT,Chardan Capital Keeps Their Buy Rating on Editas Medicine (EDIT),12/6/2022 7:45:11 PM
EDIT,Editas Medicine (EDIT) Receives a Hold from Barclays,11/19/2022 1:15:17 AM
EDIT,"Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment",11/18/2022 8:51:52 PM
EDIT,Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings,11/17/2022 8:32:03 PM
EDIT,Morgan Stanley Sticks to Its Sell Rating for Editas Medicine (EDIT),11/8/2022 4:36:21 PM
EDIT,Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Editas Medicine (EDIT),11/4/2022 1:21:46 AM
EDIT,What 5 Analyst Ratings Have To Say About Editas Medicine,11/3/2022 7:16:46 PM
EDIT,Chardan Capital Sticks to Their Buy Rating for Editas Medicine (EDIT),11/2/2022 8:45:21 PM
EDIT,Editas Medicine Q3 2022 Earnings Preview,11/1/2022 5:15:37 PM
EDIT,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Thermo Fisher (TMO), IQVIA Holdings (IQV) and Editas Medicine (EDIT)",10/28/2022 2:11:50 AM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update,10/26/2022 12:30:00 PM
EDIT,Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline,10/18/2022 7:44:02 PM
EDIT,Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting,10/13/2022 12:00:00 PM
EDIT,LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion,10/3/2022 1:15:01 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022",9/29/2022 4:06:56 PM
EDIT,Intellia falls as analysts react to CRISPR readouts,9/16/2022 4:16:02 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,9/1/2022 12:30:00 PM
EDIT,Biotech in recovery; but Piper Sandler cites negative fund flows,8/21/2022 4:00:16 PM
EDIT,Editas Medicine: Here’s What Might Trigger More Downside,8/19/2022 1:37:53 PM
EDIT,Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics,8/3/2022 6:58:07 PM
EDIT,Editas Medicine Q2 2022 Earnings Preview,8/2/2022 3:58:09 PM
EDIT,Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease,7/27/2022 12:30:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates,7/26/2022 12:26:00 PM
EDIT,Editas Medicine Reports Inducement Grant to New Chief Medical Officer,7/20/2022 10:30:00 PM
EDIT,"Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer",7/18/2022 1:00:00 PM
EDIT,The 3 Leaders of the Gene Editing Revolution,7/8/2022 8:12:42 PM
EDIT,BMO Initiates Coverage On This Gene Editing Spearhead,6/17/2022 8:31:42 PM
EDIT,"XPER, MOR and NGM are among after hour movers.",6/13/2022 9:58:32 PM
EDIT,Bluebird Bio drives gene therapy stocks higher after FDA review,6/7/2022 7:59:40 PM
EDIT,Editas Medicine Reports Inducement Grants to New Chief Executive Officer,6/6/2022 10:30:00 PM
EDIT,Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.,6/2/2022 3:45:27 PM
EDIT,Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting,5/18/2022 12:45:00 PM
EDIT,"The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product",5/13/2022 4:38:25 PM
EDIT,Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia,5/12/2022 10:30:00 PM
EDIT,Expert Ratings for Editas Medicine,5/9/2022 6:02:46 PM
EDIT,Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference,5/4/2022 7:30:00 PM
EDIT,Editas Medicine Q1 2022 Earnings Preview,5/3/2022 6:00:43 PM
EDIT,Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting,5/2/2022 10:31:07 PM
EDIT,Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update,4/27/2022 12:55:00 PM
EDIT,Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia,4/26/2022 4:33:22 PM
EDIT,"AVDL, CBAY and PVRB among after hour movers",4/25/2022 10:08:00 PM
EDIT,Editas Medicine stock falls ~8% after Baird cuts price target,4/18/2022 3:23:05 PM
EDIT,Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer,4/14/2022 1:30:00 PM
EDIT,Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10,4/11/2022 3:00:00 PM
EDIT,"Elon Musk promised to make 'significant improvements' as a newly appointed Twitter board member. Here are 4 proposals we expect to see, straight from Musk's own tweets.",4/10/2022 3:00:42 PM
EDIT,Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting,4/8/2022 7:00:00 PM
EDIT,Elon Musk's first move as a Twitter board member could fix one of the platform's biggest problems: A long-requested edit button,4/5/2022 6:18:00 PM
EDIT,"Russia holdout HSBC has cut references to a 'war' in Ukraine from its analyst research reports, the FT says",3/28/2022 1:15:01 PM
EDIT,Morgan Stanley projects about a third of biotechs will need financing in 2022,3/26/2022 4:00:28 PM
EDIT,Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents,3/1/2022 5:26:16 PM
EDIT,Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference,2/28/2022 10:01:00 PM
EDIT,Expert Ratings For Editas Medicine,2/25/2022 5:08:58 PM
EDIT,Editas Medicine net loss narrows as its beats on bottom line,2/24/2022 3:36:13 PM
EDIT,Editas Medicine Q4 2021 Earnings Preview,2/23/2022 5:31:15 PM
EDIT,"The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow",2/20/2022 2:06:46 PM
EDIT,"KMPH, CPSS and FSRD among after hour movers",2/18/2022 10:28:42 PM
EDIT,Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update,2/16/2022 12:15:00 PM
EDIT,51 Biggest Movers From Yesterday,2/9/2022 10:10:01 AM
EDIT,Editas Suddenly Terminates Chief Medical Officer Without An Explanation,2/8/2022 6:40:18 PM
EDIT,Editas Medicine down 7% after hours following chief medical officer termination,2/7/2022 10:23:13 PM
EDIT,Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference,1/10/2022 1:00:00 PM
EDIT,Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference,1/4/2022 12:58:00 PM
EDIT,Top 5 Moonshots for 2022 Countdown: My No. 5 Pick,12/22/2021 9:52:14 PM
EDIT,Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia,12/20/2021 1:00:00 PM
EDIT,"NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today",12/13/2021 4:13:14 PM
EDIT,"EDIT, CLNE and OPK among after hours",12/10/2021 10:00:09 PM
EDIT,Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting,11/12/2021 1:00:00 PM
EDIT,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",11/8/2021 2:24:25 PM
EDIT,Here's what Wall Street expects from Editas Medicine's earnings report,11/7/2021 3:01:13 PM
EDIT,Editas Medicine Q3 2021 Earnings Preview,11/5/2021 6:16:56 PM
EDIT,Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition,11/4/2021 2:02:00 PM
EDIT,Editas Medicine Names Bernadette Connaughton to Board of Directors,10/28/2021 3:00:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update,10/25/2021 10:01:00 PM
EDIT,"EDIT, AUPH and DWAC among after hours",10/22/2021 9:21:37 PM
EDIT,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",10/21/2021 2:05:16 PM
EDIT,Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress,10/20/2021 3:00:00 PM
EDIT,Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful,10/19/2021 6:25:56 PM
EDIT,CRISPR draws mixed views from analysts after data for allogeneic CAR-T therapy,10/13/2021 12:15:07 PM
EDIT,Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting,10/7/2021 2:00:00 PM
EDIT,Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference,9/30/2021 2:00:00 PM
EDIT,"4 Top Stock Trades for Thursday: LCID, DKNG, DLTR, EDIT",9/29/2021 9:49:34 PM
EDIT,"Catalyst watch for next week: Amazon, TotalEnergies and EV trucks in the spotlight",9/24/2021 7:00:57 PM
EDIT,3 Moonshot Stocks Hidden in Cathie Wood’s Portfolios,9/22/2021 8:57:12 PM
EDIT,7 Gene Editing Stocks Promising to Change our DNA,9/15/2021 4:45:22 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021",9/10/2021 4:05:59 PM
EDIT,Editas Medicine Names Emma Reeve to Board of Directors,9/8/2021 3:00:00 PM
EDIT,Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September,9/7/2021 10:00:00 PM
EDIT,"Forget About the Genomic Revolution, the Proteomic Revolution Is Coming",9/3/2021 9:30:07 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,9/2/2021 2:00:00 PM
EDIT,60 Biggest Movers From Yesterday,8/24/2021 11:11:29 AM
EDIT,35 Stocks Moving In Monday's Mid-Day Session,8/23/2021 6:01:23 PM
EDIT,Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting,8/20/2021 10:20:00 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021",8/9/2021 4:24:01 PM
EDIT,99 Biggest Movers From Yesterday,8/6/2021 11:01:47 AM
EDIT,"Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today",8/5/2021 7:34:07 PM
EDIT,Editas Medicine Announces Second Quarter 2021 Results and Business Updates,8/4/2021 1:00:00 PM
EDIT,Notable earnings before Wednesday's open,8/3/2021 2:01:21 PM
EDIT,Editas Medicine earnings: here's what Wall Street expects,8/2/2021 3:02:05 PM
EDIT,"Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the...",7/29/2021 3:00:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update,7/28/2021 1:00:00 PM
EDIT,"Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer",7/26/2021 3:00:00 PM
EDIT,The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend,7/24/2021 9:30:02 PM
EDIT,7 Best ETFs to Buy That Will Make Your World a Better Place,7/22/2021 4:10:40 PM
EDIT,Editas Stock Isn’t Worth Buying This Early Into Treatment Development,7/21/2021 2:10:21 PM
EDIT,The Top 3 Gene Editing Stocks to Own for the Next Decade,7/12/2021 5:03:48 PM
EDIT,Gene editing stocks pare gains after Intellia-led rally last week,7/6/2021 7:31:53 PM
EDIT,The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century,7/1/2021 11:30:29 AM
EDIT,Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR,6/30/2021 7:53:24 PM
EDIT,Gene editing stocks buoyed in afternoon trading by Intellia CRISPR success,6/28/2021 6:25:01 PM
EDIT,17 Stocks to Buy for the Dawn of Global AI Dominance,6/23/2021 3:48:59 PM
EDIT,Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer,6/15/2021 10:01:00 PM
EDIT,Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth,6/14/2021 3:00:00 PM
EDIT,Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association...,6/11/2021 12:00:00 PM
EDIT,Merck spinoff closes higher despite neutral views; Mirati gains on Citi upgrade; more in today’s analyst action,6/4/2021 12:23:14 PM
EDIT,"The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues",5/5/2021 1:43:29 PM
EDIT,Editas Medicine Q1 2021 Earnings Preview,5/4/2021 6:03:00 PM
EDIT,Editas Medicine earnings: here's what to expect,5/3/2021 3:01:44 PM
EDIT,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",5/1/2021 7:19:25 PM
EDIT,Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update,4/28/2021 1:01:00 PM
EDIT,7 Stocks to Buy for May,4/27/2021 5:23:23 PM
EDIT,54 Biggest Movers From Friday,4/19/2021 11:19:22 AM
EDIT,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,4/16/2021 9:04:01 PM
EDIT,Investing in CRISPR Stocks: Ultimate Genetic Editing Guide,4/15/2021 1:00:20 PM
EDIT,Editas is seen by Credit Suisse as a pioneer in CRISPR gene editing,3/22/2021 4:56:58 PM
EDIT,"Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today",3/10/2021 6:26:42 PM
EDIT,"The Past Week's Most Notable Insider Buys: Editas, Exxon Mobil, Wayfare And More",3/6/2021 7:14:15 PM
EDIT,Editas Medicine CEO buys company shares on the dip,3/4/2021 10:07:06 PM
EDIT,"Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021",3/1/2021 4:14:41 PM
EDIT,Truist downgrades shares of Editas Medicine,2/26/2021 2:20:29 PM
EDIT,Editas falls again as quarterly loss widens amid revenue slip,2/25/2021 2:24:41 PM
EDIT,Notable earnings before Thursday's open,2/24/2021 5:49:38 PM
EDIT,Here's what Wall Street expects from Editas Medicine's earnings report,2/23/2021 3:01:52 PM
EDIT,"The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings",2/20/2021 3:36:28 PM
EDIT,Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update,2/18/2021 10:02:00 PM
EDIT,Bluebird bio extends losses amid analyst downgrades following trial pause,2/16/2021 7:25:37 PM
EDIT,Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer,2/8/2021 2:00:00 PM
EDIT,"Sana prices upsized IPO at $25, above the expected range, trades today",2/4/2021 12:52:45 PM
EDIT,"The InvestorPlace Q&A: Genomics, Telehealth and the Future of Healthcare with the ANEW ETF",1/27/2021 1:21:28 PM
EDIT,2 Science-Fiction Stocks to Play This Emerging Megatrend,1/22/2021 9:23:40 PM
EDIT,Gene editors raise equity as shares climb amid investor interest,1/21/2021 9:50:54 PM
EDIT,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",1/20/2021 1:32:35 PM
EDIT,Editas Medicine Announces Offering of Common Stock,1/19/2021 10:01:00 PM
EDIT,7 CRISPR Stocks for the Future of Medicine,1/15/2021 11:12:44 PM
EDIT,84 Biggest Movers From Yesterday,1/12/2021 11:00:12 AM
EDIT,"Editas Medicine stock slumps 15%, chief scientific officer to retire, provides trial updates",1/11/2021 7:14:33 PM
EDIT,ARK Investment’s Wood will talk markets in big week for biotech: Sector Watch,1/10/2021 10:01:13 PM
EDIT,NASDAQ Biotech Index crosses 5K mark as vaccine makers and gene-editors surge,1/8/2021 5:35:45 PM
EDIT,Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference,1/4/2021 10:05:00 PM
EDIT,62 Biggest Movers From Yesterday,12/30/2020 11:03:31 AM
EDIT,45 Stocks Moving In Tuesday's Mid-Day Session,12/29/2020 6:02:23 PM
EDIT,Are Genomic Stocks The Next FANG Stocks?,12/24/2020 1:25:27 PM
EDIT,"The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes",12/22/2020 1:45:09 PM
EDIT,Editas leads a biotech rally of gene editors,12/21/2020 9:29:56 PM
EDIT,"Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors",12/17/2020 10:05:00 PM
EDIT,Editas surges 26% as Wells Fargo sizes up SCD candidates,12/10/2020 8:09:48 PM
EDIT,Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA,12/9/2020 10:01:00 PM
EDIT,"Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia ",12/5/2020 4:00:00 PM
EDIT,"EDIT, WES, NM and TRVG among after-hours movers",11/27/2020 7:06:08 PM
EDIT,Editas Medicine Reports Inducement Grants to New Chief Medical Officer,11/10/2020 10:01:00 PM
EDIT,Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit,11/9/2020 10:05:00 PM
EDIT,Editas Medicine Announces Third Quarter 2020 Results and Update,11/5/2020 10:02:00 PM
EDIT,Notable earnings after Thursday's close,11/4/2020 10:35:58 PM
EDIT,"Inspire Medical Systems, GW Pharmaceuticals leads healthcare gainers; Esperion Therapeutics, Aurinia Pharmaceuticals among major losers",11/3/2020 4:01:56 PM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update,10/29/2020 9:01:10 PM
EDIT,CRISPR gene editing discoverers share Nobel Prize,10/7/2020 10:38:16 AM
EDIT,Editas Medicine to Participate in Upcoming Investor Conference,10/1/2020 2:00:10 PM
EDIT,"Pre-market Movers In Healthcare Sector: TLSA, APDN, AVEO, TNXP, ETON… ",9/16/2020 12:48:31 PM
EDIT,Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference,9/11/2020 1:00:10 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,9/4/2020 2:00:10 PM
EDIT,Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease,8/24/2020 2:30:10 PM
EDIT,5 Disruptive Biotech Stocks to Buy for the Future That Is Here,8/13/2020 6:19:25 PM
EDIT,Earnings-related names dominate premarket losers,8/7/2020 12:18:51 PM
EDIT,Editas Medicine Announces Second Quarter 2020 Results and Update,8/6/2020 10:05:10 PM
EDIT,What Wall Street expects from Editas Medicine's earnings,8/5/2020 3:04:13 PM
EDIT,Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline,7/29/2020 2:00:10 PM
EDIT,Editas Medicine Appoints Gad Berdugo as Chief Business Officer,7/27/2020 10:01:10 PM
EDIT,Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update,7/23/2020 10:01:10 PM
EDIT,Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing,7/7/2020 3:00:10 PM
EDIT,Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares,6/26/2020 10:05:10 PM
EDIT,Editas Medicine Announces Pricing of Offering of Common Stock,6/24/2020 3:48:22 AM
EDIT,Editas Medicine Announces Offering of Common Stock,6/23/2020 10:21:25 PM
EDIT,Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease,6/12/2020 12:00:10 PM
EDIT,Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies,5/15/2020 3:20:10 PM
EDIT,Editas Medicine earnings preview: what to expect,5/7/2020 3:02:03 PM
EDIT,Editas Medicine Q1 Earnings Preview,5/6/2020 4:06:11 PM
EDIT,Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update,4/30/2020 2:05:10 PM
EDIT,"Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers",4/29/2020 3:00:10 PM
EDIT,7 Biotech Stocks to Buy and Hold in 2020,3/16/2020 2:31:48 PM
EDIT,The Top 3 Gene-Editing Stocks to Own in 2020,3/11/2020 3:42:14 PM
EDIT,"CVS, UNH among premarket gainers",3/4/2020 2:15:14 PM
EDIT,Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update,2/26/2020 10:02:00 PM
EDIT,Notable earnings after Wednesday's close,2/25/2020 10:35:42 PM
EDIT,Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update,2/19/2020 10:02:00 PM
EDIT,Intellia up 5% on new data from CRSPR/Cas9 programs,2/10/2020 4:25:33 PM
EDIT,Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference,1/13/2020 3:00:00 PM
EDIT,Editas Medicine Reports Inducement Grants to New Chief Financial Officer,1/10/2020 10:30:00 PM
EDIT,Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth,1/9/2020 3:00:00 PM
EDIT,Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference,1/2/2020 3:00:00 PM
EDIT,"Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia",12/10/2019 12:00:10 AM
EDIT,Editas Medicine Announces Third Quarter 2019 Results and Update,11/12/2019 1:02:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update,11/5/2019 2:00:00 PM
EDIT,"Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer",10/28/2019 11:55:05 PM
EDIT,Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases,10/16/2019 12:15:00 AM
EDIT,Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines,10/7/2019 1:00:00 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,10/1/2019 2:00:00 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,8/29/2019 2:00:00 PM
EDIT,Editas Medicine Announces Second Quarter 2019 Results and Update,8/6/2019 10:15:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update,7/30/2019 10:02:00 PM
EDIT,Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10,7/25/2019 3:00:00 PM
EDIT,Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association,6/15/2019 5:30:00 PM
EDIT,Editas Medicine Announces First Quarter 2019 Results and Update,5/7/2019 10:01:00 PM
EDIT,Editas Medicine earnings: here's what Wall Street expects,5/5/2019 3:01:52 PM
EDIT,Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update,4/30/2019 10:01:00 PM
EDIT,Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10),4/29/2019 3:19:37 PM
EDIT,Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms,4/3/2019 1:00:00 PM
EDIT,Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update,2/28/2019 10:01:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results,2/21/2019 10:02:00 PM
EDIT,"Editas Medicine Names David Scadden, M.D., to Board of Directors",2/6/2019 3:00:00 PM
EDIT,"6 Top Losers In Healthcare Sector (EDIT, RNN, COCP...) ",1/23/2019 5:13:37 AM
EDIT,Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10),1/21/2019 5:00:00 PM
EDIT,Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference,1/7/2019 3:00:00 PM
EDIT,Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference,1/2/2019 2:30:00 PM
EDIT,Editas Medicine Announces Transition of Chief Financial Officer,12/21/2018 3:00:00 PM
EDIT,Editas Medicine Names Cynthia Collins to Board of Directors,12/10/2018 3:00:00 PM
EDIT,Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia,12/3/2018 1:35:00 AM
EDIT,Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101,11/30/2018 1:30:00 PM
EDIT,Editas Medicine Announces Third Quarter 2018 Results and Update,11/7/2018 10:01:00 PM
EDIT,Editas Medicine earnings preview: what Wall Street is expecting,11/5/2018 3:02:36 PM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results,10/31/2018 9:01:00 PM
EDIT,Editas Medicine Grows Scientific Leadership with Two New Appointments,10/1/2018 3:00:00 PM
EDIT,Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference,9/10/2018 7:58:34 PM
EDIT,Editas Medicine Announces Transition of Chief Medical Officer,8/27/2018 10:01:00 PM
EDIT,Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process,8/16/2018 10:01:00 PM
EDIT,Editas Medicine Announces Second Quarter 2018 Results and Update,8/6/2018 10:05:00 PM
EDIT,Editas Medicine earnings: here's what Wall Street expects,8/4/2018 3:01:29 PM
EDIT,Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results,7/30/2018 10:02:00 PM
EDIT,"A blockbuster gene-editing tool has been linked to cancer — here's how worried you should be (EDIT, NTLA, CRSP)",6/13/2018 7:09:03 PM
EDIT,"A troubling link has been found between a cutting-edge gene-editing technology and cancer — and it's sending biotech stocks tumbling (CRSP, EDIT, NTLA)",6/11/2018 6:54:03 PM
EDIT,Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human PrimatesPresentation at the Annual Meeting of the American Society of Gene & Cell Therapy,5/18/2018 11:00:00 PM
EDIT,Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference,5/8/2018 2:00:00 PM
EDIT,BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67,5/3/2018 11:00:58 PM
EDIT,Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual MeetingOral presentation of tolerability...,4/30/2018 7:30:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results,4/26/2018 10:01:00 PM
EDIT,BRIEF-Editas Medicine Names James Mullen As Chairman Of Board,3/28/2018 3:27:34 PM
EDIT,Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update,3/6/2018 10:01:00 PM
EDIT,Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases,2/28/2018 3:00:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results,2/27/2018 10:01:00 PM
EDIT,"Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors",2/16/2018 3:00:00 PM
EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,2/8/2018 10:01:00 PM
EDIT,"AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars ",1/30/2018 2:19:19 AM
EDIT,"ARRY Shines A BEACON, So Long To JUNO And BIVV, Exciting Time Ahead For GEMP ",1/23/2018 2:06:55 AM
EDIT,"AXON Makes No Headway, BABY Falls, BOLD Subdued, EDIT Slips ",1/9/2018 5:44:13 AM
EDIT,Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference,1/8/2018 3:00:00 PM
EDIT,Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference,1/3/2018 2:57:52 PM
EDIT,Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-ThalassemiaExperiments support opportunities to develop best-in-class therapies for...,12/12/2017 12:00:00 AM
EDIT,"Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock",12/6/2017 1:00:00 PM
EDIT,"Editas Medicine, Inc., Announces Offering of Common Stock",12/5/2017 10:17:01 PM
EDIT,"Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team",11/14/2017 1:00:00 PM
EDIT,Editas Medicine Announces Third Quarter 2017 Results and Update,11/7/2017 10:03:00 PM
EDIT,Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results,11/3/2017 1:00:00 PM
EDIT,"Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceProductive gene editing rates with EDIT-101 were stable over six months in transgenic mice",10/19/2017 6:45:00 PM
EDIT,Editas Medicine to Participate in Investor Conferences in October,10/3/2017 2:00:00 PM
EDIT,"DXCM Falls On CGM Rivalry, ZYNE Firms Up, SPPI In Limelight, Big Day Awaits MNKD ",9/29/2017 4:19:56 AM
EDIT,Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10,9/26/2017 10:01:00 PM
EDIT,"Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte",9/15/2017 1:05:00 PM
EDIT,Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)Massachusetts Eye and Ear named as first site for the study,9/12/2017 2:00:00 PM
EDIT,"Gainers & Losers Of Aug.17: GTHX, CDTX, KMDA, ACHC, EDIT... ",8/18/2017 3:49:17 AM
EDIT,"Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP... ",8/11/2017 3:43:10 AM
EDIT,"Gainers & Losers Of Aug.7: MYOK, NXTM, MRNS, GEMP, ZYNE... ",8/8/2017 4:57:56 AM
EDIT,"Gainers & Losers Of June 7: NH, CRUS, PTCT, ANAB, ACRX... ",6/8/2017 6:15:07 AM
EDIT,"Gainers & Losers Of May 30: PTGX, ECYT, NTLA, EDIT, CNCE... ",5/31/2017 3:42:56 AM
EDIT,"Biotech Stocks on Investors' Radar -- Editas, Intra-Cellular, Aralez Pharma, and Catabasis Pharma",3/21/2017 12:35:00 PM
EDIT,"FDA Panel Snubs ENDP, Watch Out For TCON, MRK's Keytruda Scores Another Win ",3/15/2017 7:15:27 AM
EDIT,"Allergan just got exclusive access to a treatment that could revolutionize how we treat genetic diseases (AGN, EDIT)",3/14/2017 1:53:22 PM
EDIT,"ARDX Kidney Drug Passes Phase 3 Study, EDIT Up On CRISPR News, FDA Nod For VRX ",2/16/2017 10:31:12 AM
